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Fafián-Labora et al. demonstrate that
small extracellular vesicles isolated from
young human donor fibroblasts (sEV-Ys)
possess glutathione-S-transferase
(GST)-intrinsic activity. Through this
activity, sEV-Ys ameliorate senescence
and aging by increasing the antioxidant
capacity of old fibroblasts and old mice,
thus preventing lipid peroxidation.ll
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https://doi.org/10.1016/j.cmet.2020.06.004SUMMARYAging is a process of cellular and tissue dysfunction characterized by different hallmarks, including cellular
senescence. However, there is proof that certain features of aging and senescence can be ameliorated. Here,
we provide evidence that small extracellular vesicles (sEVs) isolated fromprimary fibroblasts of young human
donors ameliorate certain biomarkers of senescence in cells derived from old and Hutchinson-Gilford proge-
ria syndrome donors. Importantly, sEVs from young cells ameliorate senescence in a variety of tissues in old
mice. Mechanistically, we identified sEVs to have intrinsic glutathione-S-transferase activity partially due to
the high levels of expression of the glutathione-related protein (GSTM2). Transfection of recombinant GSTM2
into sEVs derived from old fibroblasts restores their antioxidant capacity. sEVs increase the levels of reduced
glutathione and decrease oxidative stress and lipid peroxidation both in vivo and in vitro. Altogether, our data
provide an indication of the potential of sEVs as regenerative therapy in aging.INTRODUCTION
Aging is described as the functional time-dependent decline in tis-
sue homeostasis affecting several organs in an individual. This
decline ismediatedby theactivationofcertainmolecularandcellular
signatures that comprise twoof themain hallmarks of aging: disrup-
ted intercellular communication andactivationof the cellular pheno-
type termed senescence (López-Otı́n et al., 2013). Although no sin-
gle biomarker for the identification of senescent cells has been
identified so far, the main characteristics are a stable exit from the
cell cycle and a compromised intercellular communication termed
senescence-associated secretory phenotype, or SASP (Coppé
et al., 2010; Fafian-Labora and O’Loghlen, 2020; Kuilman et al.,
2010; Lee and Schmitt, 2019; Muñoz-Espı́n and Serrano, 2014).Context and Significance
In this work, we investigate novel strategies that could lead to
mice has the ability to rejuvenate old mice, we wanted to det
released by cells, were involved. We find that EVs from youn
and human cells, as they are very effective natural antioxidant
logical strategies to achieve rejuvenation, but most drugs are
toxicity or immunogenicity; thus, this study opens new avenue
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This is an open access article undThe SASP is mainly formed by soluble factors, matrix remod-
eling enzymes, and extracellular vesicles (EVs) (Borghesan et al.,
2019; Coppé et al., 2010; Fafian-Labora and O’Loghlen, 2020;
Jeon et al., 2019; Takahashi et al., 2017). It is hypothesized
that chronic SASP is the main culprit for inducing aging and
age-related disease. Although the mechanisms involved are
not well characterized, it is thought to be partially due to non-
cell-autonomous signaling (Acosta et al., 2013; Borghesan
et al., 2019; McHugh and Gil, 2018).
Senescence can also favor partial tissue reprogramming
in vitro and in vivo, which in turn ameliorates cellular and physi-
ological hallmarks of aging through epigenetic remodeling
and soluble factors (Liu et al., 2011; Mosteiro et al., 2016;
Ocampo et al., 2016). Interestingly, this complements previousimproving wellbeing throughout life. As blood from young
ermine if extracellular vesicles (EVs), balloon-like structures
g donor cells rejuvenate certain features of aging in mice
s. At present, there is a huge effort to determine pharmaco-
toxic. Instead, EVs are a natural source and do not induce
s for strategies to improve lifelong health and wellbeing.
6, July 7, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 71
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Functional Analysis of Different Fractions of the Conditioned Media of Young Donor Cells on Old Recipient Fibroblasts
(A) Three (AG06240, AG13152, and AG13222) to four (AG16086, AG06240, AG13152, and AG13222) different cells derived from old donors were treated with
pooled conditioned media (CM) from 3–4 young cells and separated fractions (SF, soluble fraction; large and small extracellular vesicles, lEVs and sEVs,
(legend continued on next page)
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OPEN ACCESSArticlestudies where blood-borne factors were shown to rejuvenate
mice of old age (Conboy et al., 2005; Scudellari, 2015; Villeda
et al., 2014). Altogether, these findings show the potential of
non-cell-autonomous signaling in ameliorating age-associated
hallmarks.
It has been recently shown that small EVs (sEVs) play a previ-
ously uncharacterized role in senescence, aging, and age-
related diseases (Basisty et al., 2020; Borghesan et al., 2019;
Jeon et al., 2019; Takahashi et al., 2017; Yoshida et al., 2019);
thus, here we aim to determinewhether sEVs could also be impli-
cated in ameliorating biomarkers of senescence and aging
in vitro and in vivo. Our data show that sEVs derived from fibro-
blasts isolated from young human healthy donors (sEV-Ys) have
the ability to prevent biomarkers of senescence characteristic of
old human donors, cells undergoing oncogene-induced senes-
cence, and fibroblasts derived from Hutchinson-Gilford progeria
syndrome (HGPS), a severe accelerated form of aging. Interest-
ingly, although the soluble fraction (SF) also ameliorated the pro-
liferation arrest characteristic of senescence, its effect was
modest in comparison with sEVs while large EVs (lEVs) displayed
no functionality. Importantly, we show that sEV-Ys have intrinsic
GST activity in contrast with the SF and have increased protein
expression levels of glutathione-S-transferase mu 2 (GSTM2).
Furthermore, sEV-Ys have the ability to reverse the accumulation
of reactive oxygen species (ROS) and prevent lipid peroxidation
in vitro and in certain organs in mice of old age. Altogether, we
show that sEV-Ys can ameliorate a variety of features of senes-
cence and aging in vitro and in vivo in certain organs.
RESULTS
Small Extracellular Vesicles Isolated fromYoung Human
Donor Fibroblasts Ameliorate Biomarkers of
Senescence In Vitro
We hypothesize that fibroblasts derived from young donors have
the ability to ameliorate senescence-related features in fibro-
blasts from old donors, via non-cell-autonomous mechanisms.
First, we confirmed the presence of biomarkers of senescence
in old versus young fibroblasts (Figure S1A) (Rapisarda et al.,
2017). To address our hypothesis, we pooled the conditioned
media (CM) derived from four different human primary fibroblasts
isolated from young donors (GM05399, GM00969, GM05565,
and GM05758; ranging 1–3 years). We next dissected the CMrespectively). Quantification of the percentage of cells staining positive for marke
(middle), and p21CIP1 (right) staining. Data represent the mean ± SEM of 2 indepe
medium as control. t test analyses were performed. *p < 0.05; **p < 0.01; ns, no
(B) Representative pictures of p16INK4A and BrdU staining by IF in the old cell lin
(C) Representative pictures of AG16086 (old fibroblast) treated with sEVs derived
(D) Growth curve representing the mean ± SEM of the relative cell number of 4 o
different time points shown in days. FBS 10% is control. Two-way ANOVA was
(E and F) Representative pictures of senescence-associated b-galactosidase (S
treated with sEVs from young or old donors (F). Representative images from AG1
(G) Schematic representation of the transmission of the rejuvenation potential of s
of H-RasG12V (iRAS cells); secondary and tertiary senescence are iRAS cells trea
(H) qPCR to determine SASP mRNA levels of cells undergoing either primary or
(I) Long-term treatment of 4 young or 4 old donor cells with the indicated sEVs ever
Proliferation was measured by quantifying cell number ± SEM during different da
(B, C, and E) Scale bar, 50 mm.
See also Figure S1.into soluble and vesicular fractions and investigated which frac-
tion could ameliorate senescence. Thus, we compared the com-
plete CM fraction, with an equivalent volume of CM divided into
SF, lEV, and sEV fractions (Figure S1B), by serial ultracentrifuga-
tion as done previously with some modifications (Borghesan
et al., 2019; Théry et al., 2018). Next, we individually treated
four human primary fibroblast lines derived from old donors
(AG16086, AG06240, AG13152, and AG13222; range 67–81
years) with all the different fractions from young and old fibro-
blasts. Media with EV-depleted serum was used as negative
control (FBS 10%). As shown in Figures 1A and 1B, the pooled
CM from young donors prevented the proliferation arrest
(measured by quantifying BrdU incorporation by immunofluores-
cence [IF]) and the number of cells staining positive for p16INK4A
and p21CIP1, all characteristics of senescence and old donor
cells (Figure S1A) (Rapisarda et al., 2017). We found the SF to
have slightly less ability to ameliorate these senescence-related
biomarkers in comparison with the sEV fraction, while the lEV
fraction had no effect on modifying these biomarkers in old
donor cells (Figures 1A–1C and S1C). Next, we characterized
the EV fraction and found that sEVs and lEVs showed a different
EV distribution, mean particle size, and number by performing
nanoparticle tracking analysis (NTA) (Figures S1D and S1E),
while sEVs presented EV-related proteins such as ALIX and
TSG101 (Figure S1F) and lacked endoplasmic reticulum con-
taminants such as calnexin (Figure S1G). It was also observed
that old donors release more sEVs and lEVs than young donors
(Figure S1H). Next, we determined the proliferative capacity of
old donor cells treated for 72 h with the SF and sEVs—as lEVs
had no functionality—replated and counted by DAPI staining at
different days. The sEVs noticeably prevented the cell-cycle ar-
rest in old donor cells in comparison with the SF (Figure 1D)
11 days after treatment (day 8). However, it cannot be excluded
that longer-term experiments would be needed to confirm this.
We further looked at additional biomarkers of senescence by
qPCR related to the cell cycle and the SASP in the old cell line
AG16086 treated with the SF and sEVs isolated from the young
cell GM05399 (Figure S1I). The heatmap shows the potential of
the sEV fraction from young cells in ameliorating senescence
markers characteristic of old donors. We also validated some
of these mRNA in all four old donor lines treated with pooled
sEVs derived from young cells (hereafter named sEV-Ys) (Fig-
ure S1J). Next, we determined the activity of senescence-rs of senescence: proliferation measured by BrdU incorporation (left), p16INK4A
ndent experiments in 3–4 old cell lines. FBS 10% represents cells treated with
n-significant.
e AG16086 treated with CM from old (CM-OLD) or young cells (CM-YOUNG).
from old (sEV-OLD) or young (sEV-YOUNG) cells.
ld donor cell lines treated with either SF or sEVs from young or old donors at
performed. ***p < 0.001.
A-b-Gal) activity (E) and quantification of IL-8 staining by IF in 4 old cell lines
6086 are shown. t test analysis was performed. **p < 0.01; ns, non-significant.
EVs. Primary senescence are donor cells undergoing senescence by activation
ted with sEVs isolated from either iC cells (iCsEV) or iRAS cells (RASsEV).
secondary senescence. Mean of 3 independent experiments is shown.
y 72 h. Young and old donor cells withmedia (FBS 10%) were used as controls.
ys. Two-way ANOVA statistical analysis was done. ***p < 0.001.
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of IL-8 by IF, both biomarkers of senescence. In fact, treatment
of all four old donor cells with sEV-Ys decreased the percentage
of cells staining positive for SA-b-Gal and IL-8 (Figures 1E and
1F). Therefore, our data show that sEV-Ys have the ability to
ameliorate certain markers of senescence in old cells.
The Effect of sEV-Ys Ameliorating Senescence-Related
Biomarkers Is Transmitted
Our previous results suggest that sEV-Ys can ameliorate the
senescence-associated phenotype. Next, we questioned
whether these effects could be maintained in old donor fibro-
blasts receiving sEV-Ys. To address this question, we took
advantage of early passage human primary foreskin fibroblasts
(HFFF2) expressing the oncogene H-RASG12V (iRAS) in a tamox-
ifen (4OHT)-inducible vector, which activates senescence and its
corresponding control (iC) (Borghesan et al., 2019; Rapisarda
et al., 2017). HFFF2 are derived from 14- to 18-week-old human
fetus and their sEVs behave as sEV-Ys. Next, we compared
changes in the mRNA levels by qPCR in cells undergoing senes-
cence, iC and iRAS (primary senescence), and in iRAS cells
treated with sEVs from either iC (iCsEVs, equivalent to sEV-Ys)
or iRAS (RASsEVs, equivalent to sEV-Os) (secondary senes-
cence) (Figure 1G). The heatmap in Figure 1H shows that iRAS
cells treated with iCsEVs have the ability of repress mRNA
transcripts related to the SASP and also cell-cycle inhibitors
generally upregulated during senescence (Figure S1K). This
transmission effect is maintained through tertiary senescence
measured by IF staining of different markers of senescence,
although to a lesser extent (Figure S1L). We and others have
described that cells undergoing senescence release a larger
number of particles or sEVs as a characteristic of the SASP (Bor-
ghesan et al., 2019; Takahashi et al., 2017). In fact, we also
observe a decrease in the release of sEVs during secondary
senescence (Figure S1M). In addition, the proliferative advan-
tagemediated by treatment with sEV-Ys every 72 h ismaintained
long term in old donor cells and in iRAS cells, although to a lesser
extent than young and iC cells (Figures 1I and S1N). Altogether,
our data show that sEVs derived from young cells ameliorate
different biomarkers of senescence, which can be further
transmitted.
sEV-Ys Ameliorate Cellular Phenotypes Associated with
Aging in HGPS-Derived Fibroblasts
To determine if sEV-Yswithin the CMhad the potential to amelio-
rate biomarkers of aging, we took advantage of primary
fibroblasts derived from patients with a severe form of premature
aging, HGPS, which present biomarkers of aging and senes-
cence (Figure S2A) (Burtner and Kennedy, 2010; Ocampo
et al., 2016; Liu et al., 2011). Four different HGPS-derived fibro-
blasts (AG11572, AG06917, AG07493, and AG10677; ranging 2–
4 years old) were treated individually with pooled CM or different
fractions derived from either HGPS or young cells as in Figure 1.
As shown in Figures 2A–2C, we could observe a similar pattern
as with the old donors (Figure 1), where the SF and sEV fractions
ameliorated the cell-cycle arrest characteristic of HGPS cells by
quantifying the number of cells incorporating BrdU by IF. Howev-
er, only the sEV fraction could ameliorate the high levels of
expression of p16INK4A and p21CIP typical of HGPS cells (Figures74 Cell Metabolism 32, 71–86, July 7, 20202A–2C), with the lEV and SF fractions having little to no effect
(Figures S2B and S2C). This was further confirmed by deter-
mining by qPCR themRNA levels of additional markers of senes-
cence related to cell cycle and the SASP in the HGPS cell line,
AG11572, with little to no effect from the SF fraction (Figure S2D).
As with the sEVs derived from old donors, we could also observe
an increase in sEV number from HGPS cells compared to young
donors by NTA with no change in particle size (Figures S2E and
S2F). Furthermore, treatment of four HGSP cells with pooled
sEV-Ys prevented the proliferation arrest characteristic of these
cells with no effect observed from the SF at longer-term treat-
ment (Figure 2D).
sEV-Ys Are Enriched in Antioxidants and Overcome the
Oxidative Stress Characteristic of Old Donor Fibroblasts
In order to determine proteins enriched in sEV-Ys that could be
responsible for ameliorating senescence, we took advantage
of a previous proteomics analysis performed in our lab for
sEVs derived from iC, iRAS, or etoposide-treated HFFF2, which
induces senescence (Borghesan et al., 2019; Rapisarda et al.,
2017). We determined which proteins were enriched with statis-
tical significance (FDR 10%) in iC in comparison with both iRAS-
and etoposide-treated fibroblasts. Altogether, we identified 55
common proteins that were highly enriched in iCsEVs in compar-
ison with both iRAS or etoposide sEVs (Figure 3A; Table S1).
STRING and Reactome pathway analysis for these 55 proteins
showed that some of these proteins grouped into the glutathione
conjugation pathway (Figures 3B and 3C). In fact, GSTM2 is one
of the proteins most highly enriched in iCsEVs in comparison
with sEVs derived from iRAS and sEVs from etoposide-treated
cells. Analysis of sEVs derived from young fibroblasts shows
an enrichment in GSTM2 by immunoblotting in comparison
with sEVs derived from old and HGPS-derived cells (Figures
3D and 3E). GSTM2 was also enriched in sEVs isolated from
proliferating cells in comparison with sEVs derived from cells un-
dergoing senescence by other triggers, such as iRAS or etopo-
side treatment (Figure S3A). To further assess that GSTM2 was
found within the sEV fraction, we performed sEV Optiprep
gradient isolation. Immunoblot analysis of different sEV fractions
shows that GSTM2 floats at the same density as sEVs that
contain TSG101 (Figure 3F). GSTM2 was also found to be highly
expressed in young cell lysates in comparison with old and
HGPS (Figure S3B). As the main activity of GST is to counteract
the detrimental effects of ROS (Townsend and Tew, 2003), we
next assessed the potential of sEV-Ys in reverting the accumula-
tion of ROS in old donor cells. For this we measured 8-oxodG, a
marker of oxidative stress. Quantification of old fibroblasts stain-
ing positive for 8-oxodG shows that fibroblasts treated with the
CM from young cells reversed the accumulation of ROS in old
cells (Figure 3G). Interestingly, we could confirm that only the
sEV fraction had the potential to prevent ROS accumulation by
quantifying 8-oxodG-positive cells, while the SF and lEV frac-
tions had less effect (Figures 3G, 3H, and S3C). We next
confirmed the antioxidant potential of sEV-Ys by measuring
intracellular ROSwith an alternative technique, H2-DCFDAmea-
surement by fluorescence-activated cell sorting (FACS), in sEV-
Y-treated old cells (Figure S3D). As an increase in ROS can lead
to DNA damage, we determined the presence of p-gH2AX. As





Figure 2. sEV-Ys Ameliorate Cellular Phenotypes Associated with Senescence in HGPS Patient-Derived Fibroblasts
(A) Three or four different cells derived from HGPS patients (AG11572, AG06917, AG07493, and AG10677) were treated with pooled conditioned media (CM) and
fractions (SF, lEV, and sEV) from 3–4 pooled young cells. The percentage of cells staining positive for BrdU (left), p16INK4A (middle), and p21CIP1 (right) was
quantified. Data represent the mean ± SEM of 2 independent experiments in 3–4 HGPS-derived cell lines. FBS 10% represents medium-treated cells as control. t
test analyses were performed. *p < 0.05; **p < 0.01; ***p < 0.001; ns, non-significant.
(B and C) Representative images for AG11572 (HGPS-derived fibroblast line), treated with (B) CM or (C) sEVs derived from either HGPS or young donors. Scale
bar, 50 mm.
(D) Long-term growth curve of 4 HGPS-derived fibroblasts treated with either SF or sEV fractions for 72 h, replated, and counted on different days. Data show the
mean ± SEM of the relative cell number along time in days. Two-way ANOVA was performed. ***p < 0.001.
See also Figure S2.
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Figure 3. sEV-Ys Are Enriched in Proteins Related to Glutathione Conjugation and Ameliorate ROS Levels in Old Donor-Derived Fibroblasts
(A) Analysis of a published proteomic analysis (Borghesan et al., 2019) on sEVs isolated from iC fibroblasts and sEVs derived from cells undergoing senescence
(iRAS and by etoposide treatment). We found 55 proteins enriched in sEVs derived from iC in comparison with sEVs from iRAS and etoposide.
(B and C) STRING (B) and Reactome pathway analysis (C) for the 55 proteins enriched in sEVs from iC highlight the glutathione metabolism pathway where
GSTM2 is highlighted.
(D) Immunoblotting for GSTM2 and ALIX in sEVs isolated from young, old, and HGPS fibroblasts loading the same number of sEVs (33 109). sEVs isolated from all
four cell lines are shown.
(E) Densitometry quantification for GSTM2 immunoblotting versus ALIX. t test analyses were performed. *p < 0.05; **p < 0.01.
(legend continued on next page)
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positive for p-gH2AX, while no differences could be observed
with the SF or the lEV fractions (Figures 3I, 3J, and S3E). Instead,
the sEV fraction had a partial effect in preventing the accumula-
tion of p-gH2AX (Figures 3I and 3J). Here, we show that GSTM2
protein expression is decreased during aging and senescence in
cells and their corresponding sEVs, and that sEV-Ys are themain
fraction ameliorating ROS and DNA damage levels in old donor
fibroblasts in comparison with the SF.
sEV-Ys Have Intrinsic GST Activity and Regulate GSH
Levels to Mediate Rejuvenation in Old Donors
It has previously been reported that sEVs can have intrinsic
metabolic activity (Iraci et al., 2017; Peruzzotti-Jametti et al.,
2018; Yoshida et al., 2019). As our proteomic analysis and
immunoblotting show that sEV-Ys have high levels of
GSTM2 (Figure 3), we next set to determine whether sEV-Ys
could have intrinsic GST activity compared to sEV-Os (Fig-
ure 4A). We also analyzed the SF fraction from young and
old donors to determine whether soluble GST activity could
be present in the SF. As shown in Figure 4A, sEV-Ys had inde-
pendent metabolic activity compared to the sEV-Os, while
none of the SF fractions had GST activity. We next determined
whether there were changes in the GST activity in old cells
treated with sEV-Ys. As we can see in Figure 4B, old recipient
cells treated with sEV-Ys have an increase in GST activity in
comparison with cells treated with sEV-Os or 10% FBS.
Next, we set out to determine the implication of blocking the
de novo synthesis of GSH by treating the old recipient cells
with increasing concentrations (20 and 40 mM) of buthionine
sulphoximine (BSO), which blocks glutamate-cysteine ligase
(GCL) complex (Gorrini et al., 2013). Treatment of old donor
cells with different concentrations of BSO was not toxic as
no changes in cell number were observed (Figure S4A). While
no effect on the ratio between reduced GSH and its oxidized
form GSSG (glutathione disulfide) (GSH/GSSG) could be
observed in old cells treated with sEVs from old donors, we
could see that sEV-Ys induced an increase in the levels of
GSH/GSSG in old cells, which was blunted when the cells
were treated with different concentrations of BSO (Figure 4C).
To confirm that BSO was preventing the synthesis of GSH, we
treated young donor cells with different concentrations of
BSO and measured the GSH/GSSG ratio (Figure S4B). Inter-
estingly, the increase in proliferation in old cells treated with
sEV-Ys and the decrease in the levels of b-Gal activity were
blunted when BSO was added (Figures 4D and 4E). Alto-
gether, these data show that sEV-Ys have intrinsic GST activ-
ity and can modulate the GSH levels in recipient cells by regu-
lating senescence in old cells.(F) sEVs were subjected to density gradient by Optiprep and different fractions
containing GSTM2.
(G) IF quantification for ROS by 8-oxodG staining in 4 old fibroblasts treated w
performed. **p < 0.01; ns, non-significant.
(H) Representative pictures for 8-oxodG staining in GM05565 (old cell line) treate
(I) IF quantification for p-gH2AX staining in 4 old fibroblasts treatedwith young don
non-significant.
(J) Pictures of p-gH2AX in AG16086 (old cell line) basal levels or treated with sEV
(H and J) Scale bar, 50 mm.
(G and I) FBS 10% is shown as negative control.
All data represent mean ± SEM in 4 different cells lines derived from old donors.GSTM2 Expression Is Partially Implicated in Preventing
Senescence in Old Donor Fibroblasts
In order to determine whether GSTM2 within sEVs regulates
senescence, we took advantage of a retroviral construct encod-
ing a myc-tagged Gstm2 construct in iC and iRAS HFFF2 cells
(Dolado et al., 2007). Expression of myc-Gstm2 in iRAS donor
cells was confirmed (Figure S4C), and a partial prevention of
the activation of senescence was confirmed by determining
the percentage of cells expressing p16INK4A and b-Gal activity
(Figure S4D). The expression levels of GSTM2 in their corre-
sponding sEVs was also confirmed (Figure S4E). Interestingly,
the presence of myc-Gstm2 within sEVs derived from iRAS cells
induced a partial decrease in SA-b-Gal activity and p16INK4A
expression levels in iRAS cells and increased their proliferative
capacity (Figures 4F, 4G, and S4F). Internalization of myc-
Gstm2 sEVs could be confirmed by immunoblot for myc tag in
the recipient cells (Figure S4G). Thus, we next asked whether
we could modify sEVs from old donors by transfecting a His-
tagged recombinant protein for human GSTM2 (rGSTM2) as
done previously (Iraci et al., 2017). Therefore, we transfected
rGSTM2 or isotype IgG into sEVs isolated from old donors, and
washed and re-purified these by size exclusion chromatography
(SEC) followed by serial ultracentrifugation and an additional
wash to avoid having excess recombinant proteins in the sEV
fraction (Figure 4H). The presence of rGSTM2 within sEVs from
old donors (rGSTM2-sEV) was confirmed by His immunoblotting
(Figure S4H). Interestingly, we found that when we transfected
rGSTM2 into sEVs from old donors and treated old cells, we pre-
vented SA-b-Gal activity (Figure 4I). rGSTM2 on its own was
used as a positive control (Figure 4I) while non-relevant recombi-
nant proteins were used as negative controls (data not shown).
Similarly, rGSTM2-sEVs downregulated the high levels of
p16INK4A expression and prevented the proliferation arrest
characteristic of old fibroblasts (Figure S4I) and p-gH2AX (Fig-
ure S4J). Altogether, we show that GSTM2 is partially respon-
sible for ameliorating certain biomarkers of senescence in
old cells.
sEV-Ys Ameliorate Cellular Biomarkers of Senescence
In Vivo
Next, we set out to evaluate if sEV-Ys could ameliorate cellular
markers of aging in 22- to 25-month-old C57BL6 mice. Here,
we focused on the role of sEV-Ys, as SF showed no antioxidant
or GST activity in vitro (Figures 3 and 4). For this, we took advan-
tage of young fibroblasts expressing an mCherry human CD63
construct to determine internalization in vivo. Thus, we injected
20 mg cherry-human CD63 sEV-Ys (termed sEV-Ys) by intraper-
itoneal (i.p.) injection or an equivalent volume of PBS twice a
week for 3 weeks and determined different markers ofwere immunoblotted for GSTM2 and TSG101 showing the presence of sEVs
ith the CM and other fractions derived from young cells. t test analyses were
d with sEV-Ys and sEV-Os or with FBS 10%.
or CMand fractions. t test analyseswere performed. **p < 0.01; ***p < 0.001; ns,
-Ys or sEV-Os.
See also Figure S3.






Figure 4. GST Activity and GSH Levels Are Important in Mediating sEV-Y Rejuvenation in Old Donors
(A) sEVs isolated from 4 different young donors have independent GST activity. sEVs from old donors and their respective SF fractions from young and old donors
do not present GST activity. t test analysis was performed. **p < 0.01.
(B) GST activity was determined in old fibroblasts treated with sEVs from either young or old donors. FBS 10%was used as a control. Data show themean ± SEM
of 4 different donor cells. t test analysis was performed. ***p < 0.001; ns, non-significant.
(C) Ratio of GSH/GSSG in old cells treated with sEVs and different concentrations (20 or 40 mM) of BSO (buthionine sulphoximine), which prevent de novo GSH
synthesis. The increase in GSH/GSSG levels when old cells are treated with sEV-Ys is prevented after BSO treatment. *p < 0.05; **p < 0.01; ns, non-significant.
(D) Relative cell number shows an increase in proliferation in old cells treated with sEV-Ys, which is prevented by GSH inhibition (BSO). **p < 0.01.
(legend continued on next page)
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cence by SA-b-Gal staining in different tissues of treated and
untreatedmice. Interestingly, we could observe that sEV-Y treat-
ment in old mice reduced the levels of SA-b-Gal staining in
different tissue sections of kidney, lung, and brown adipose tis-
sue (BAT) (Figures 5B and 5C). Furthermore, we could observe a
decrease in macrophage infiltration in the liver by SA-b-Gal, sug-
gesting a decrease in the activation of senescence in the liver as
previously described (Figures 5B and 5C) (Lee and Schmitt,
2019). Quantitative mRNA analysis of Cdkn2a in liver, kidney,
and lung showed a decreasing trend in the upregulation of
Cdkn2a characteristic of old mice upon sEV treatment (Fig-
ure 5D). However, we could only observe a reduction in the levels
of Cdkn1a upon treatment in the liver and kidney, not in the lung
(Figure S5A). Similarly, we find a reduction in the mRNA expres-
sion of different SASP factors when old mice were treated with
sEV-Ys in the liver and kidney with little to no differences in the
lung (Figures 5E and S5B). Significantly, quantitative ELISA anal-
ysis of Il-6 and GM-CSF in serum, two well-characterized SASP
factors (Acosta et al., 2008; Coppé et al., 2008; Kuilman et al.,
2008), showed a reduction in the concentration of both SASP
factors in sEV-Y-treated mice (Figure 5F). Importantly, analysis
of human CD63 in the liver and kidney of mice treated with
sEV-Ys (expressing human CD63), but not in the young or un-
treated mice, could be detected using TaqMAN probes, sug-
gesting sEV-Y internalization (Figure S5C). HFFF2 cells were
used as a positive control (Figure S5C). Interestingly, sEV-Ys
induced a slight increase in brown interscapular adipose tissue
mass (Figures S5D and S5E), which has been previously linked
to increased lifespan (Liao et al., 2011). Therefore, we show a
correlation between sEV-Y i.p. injection and a decrease in
cellular biomarkers of senescence in liver, BAT, kidney, and
serum, with some changes observed in the lung.sEV-Ys Regulate ROS andGSH Levels in OldMice In Vivo
Wehave shown that sEV-Ys regulate ROS andGSH levels in old-
derived fibroblasts (Figures 3 and 4). Next, we set to determine
whether sEV-Ys could be regulating the same pathway in vivo.
As we had seen changes in biomarkers of senescence in liver,
kidney, BAT, and serum, we determined first the levels of ROS
in these same tissues. Indeed, old mice presented high levels
of ROS in the liver and serum compared with young mice (Fig-
ure 6A). Importantly, treatment with sEV-Ys significantly reduced
the levels of ROS in these tissues, confirming the antioxidant ca-
pacity of sEV-Ys (Figure 6A), with a similar trend found in BAT
and kidney (Figure S6A). As these data correlate with our
in vitro data, we next determined if these changes in ROS could
be due to a transfer of GSTM2within sEVs, which we know is en-
riched in sEV-Ys. We therefore determined the levels of expres-
sion for GSTM2 in the liver by immunoblotting and found that,(E) SA-b-Gal activity downregulation by sEV-Ys is prevented by 20 mM BSO trea
(F and G) iC or iRAS HFFF2 cells were treated with sEVs derived from iC or iRAS e
independent experiments is shown. (F) SA-b-Gal activity was quantified and (G)
(H) Diagram of the protocol followed to transfect recombinant GSTM2 (rGSTM2)
(I) Four old donor cells were treatedwith sEVs isolated from old and young donors
donor cells on its own as a positive control. SA-b-Gal activity quantification and rep
different donor cell lines. **p < 0.01; ns, non-significant.
See also Figure S4.indeed, the levels of GSTM2decreased in oldmice but increased
upon treatment with sEV-Ys (Figure 6B), with a similar trend in
the kidney (Figure S6B). As these finding suggest that GST activ-
ity and GSH levels could be altered due to sEV-Y treatment, we
next set out to determine whether we could observe changes in
GST activity in these different tissues. In fact, GST activity was
extremely decreased in the liver and serum in old mice when
compared to young mice, while the treatment with sEV-Ys re-
verted the activity of GST to normal young levels in these tissues
(Figure 6C). A similar trend was found in the kidney and BAT,
although to a lesser extent in the latter (Figure S6C). Further-
more, RNA analysis for transcripts related to the glutathione
antioxidant pathway confirmed changes in the transcriptome
level—in particular in the master regulator Gclc—when old
mice where treated with sEV-Ys in the liver and kidney (Figures
6D and S6D). Additionally, we set out to determine whether
sEV-Ys could play a role locally by injecting 20 mg sEV-Ys in
old mice subcutaneously twice a week for 2 weeks (Figure S6E).
Although we looked at different biomarkers of senescence
including ROS and GST activity in liver, kidney, and BAT, we
could find no differences between the old mice treated with
sEV-Ys or those untreated (data not shown). However, surpris-
ingly, we did find a similar biological response as with old fibro-
blasts and oldmice with sEV-Y i.p. injection in the serum (Figures
S6F–S6H). In fact, sEV-Y treatment induced a reduction in the
levels of ROS in the serum (Figure S6F) and a concomitant in-
crease in GST activity and in the levels of reduced GSH in serum
(Figures S6G and S6H). Altogether, here we show that sEV-Ys
can regulate ROS and GST activity with a concurrent increase
in the antioxidant GSH and related mRNA transcripts in certain
tissues in old mice.sEV-Ys Decrease Lipid Peroxidation In Vivo and In Vitro
As lipid peroxidation products are main endogenous substrates
of GSTM2 (Townsend and Tew, 2003), we next investigated
whether we could observe changes using the i.p. sEV-Y treat-
ment in oldmice. For this, we determined the levels of malondial-
dehyde (MDA) and 4-hydroxynonenal (4-HNE), widely used
markers of lipid peroxidation (Binder et al., 2016). We could
indeed observe significant changes in MDA levels in the liver
and serum between young and old mice showing an increase
in lipid peroxidation in old mice (Figures 7A and 7B). In accor-
dance with our previous results, treatment of old mice with
sEV-Ys prevented the accumulation of MDA in both liver and
serum (Figures 7A and 7B), with a similar trend found in BAT
and kidney (Figure S7A). The decrease in lipid peroxidation after
sEV-Y treatment was further confirmed by 4-HNE immunoblot-
ting in the liver and BAT (Figures S7B and S7C) and immunohis-
tochemistry staining for 4-HNE in the kidney (Figure S7D). The
reduction in lipid peroxidation due to sEV-Y treatment was alsotment. *p < 0.05; **p < 0.01.
ctopically expressing myc-Gstm2 or empty vector. Themean ± SEM from three
representative images are shown. **p < 0.01; ns, non-significant.
into old sEVs.
transfected with either IgG or rGSTM2 (rGSTM2-sEV). rGSTM2was used on old
resentative pictures are shown. Quantification represents themean ± SEMof 4






Figure 5. Analysis of Different Biomarkers of Aging and Senescence in Old Mice Treated with sEV-Ys
(A) Schematic representation of the experimental settings for the sequential i.p. injection of 20 mg sEV-Ys twice aweek for 3 weeks. Five 22- to 24-month-oldmice
were used per condition.
(B andC) Immunohistochemistry (IHC) staining and quantification for SA-b-Gal in tissue sections from liver, kidney, lung, and brown adipose tissue (BAT) of young
and old mice treated with or without sEV-Ys. Nuclear Fast Red staining is also shown. Representative pictures (B) and quantification (C) of SA-b-Gal activity for 3
young and 5 mice per condition. Welch’s t test was performed.
(D) Relative Cdkn2a mRNA levels measured by qPCR in liver, kidney, and lung in young, old, and old mice treated with sEV-Ys. ANOVA was performed.
(legend continued on next page)
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OPEN ACCESSArticleconfirmed in our in vitro model by treating iRAS cells with sEVs
isolated from iRAS expressing myc-GSTM2 and determining
the levels of MDA (Figure 7C). This was further validated in old fi-
broblasts treated with sEV-Ys, which was blunted upon BSO
treatment (Figure 7D). To further confirm an implication of sEV-
Ys in ameliorating the levels of lipid peroxidation, we next treated
young HFFF2 cells with increasing concentrations of 4-HNE
(1.25, 2.5, and 5 mM), which induced senescence as shown by
the arrest in proliferation (Figure 7E) and the increase in SA-
b-Gal and p16INK4A staining by IF (Figure 7F). In fact, incubation
of 4-HNE-treated young HFFF2 with sEV-Ys ameliorated the
increase in lipid peroxidation as shown by measuring MDA con-
centration (Figure 7G). Altogether, these data show that sEV-Ys
have the ability to reduce the levels of lipid peroxidation in vitro
and in vivo.
Lipid Peroxidation Induces Senescence via Several
Pathways
In order to determine the pathway by which 4-HNE mediates
senescence, we next evaluated the effect of small interfering
RNA (siRNA) and small molecule inhibitors blocking important
pathways in senescence in 4-HNE-treated young fibroblasts.
siRNA targeting p16 (sip16), p53 (sip53), p65—a key component
of the NF-kB pathway—(sip65), and C/EBPb (siCEBP), in addi-
tion to a non-targeting control (Scr), were used. As shown in Fig-
ure S7E, we could observe an increase in the percentage of cells
expressing p16INK4A, p53, p65, and C/EBPb upon 4-HNE treat-
ment with all siRNA inducing a reduction in their respective pro-
tein levels measured by IF and quantification. Interestingly, the
induction of senescence mediated by 4-HNE was dependent
on all pathways analyzed (Figure 7F), where a reduction in the
levels of MDA were confirmed (Figure S7F), verifying the wide-
spread effect of lipid peroxidation. Importantly, treatment with
sEV-Ys prevented the accumulation of MDA induced by 4-HNE
treatment (Figure 7G). The implication of NF-kB and oxidative
stress in preventing 4-HNE senescence was further confirmed
by the use of different small molecule inhibitors targeting IKK ac-
tivity (NF-kB pathway with 20 mM CAY10576) and ROS (100 nM
NAC), where sEV-Ys were used as a positive control (Figure 7H).
A decrease in the levels of MDA using these inhibitors and the
implication of a DNA-damage response by analyzing the levels
of p-gH2AX were further confirmed (Figures S7G and S7H).
DISCUSSION
A few decades ago, the notion of rejuvenation or amelioration of
aging seemed unfeasible. However, in the last decades, the
concept of parabiosis re-emerging and the rejuvenating cellular
and tissue plasticity acquired by induced pluripotent stem cells
have changed our views on the subject (Papapetrou, 2016; Scu-
dellari, 2015). However, although some individual factors such as
Notch/TGFb signaling, oxytocin, GDF11, and MANF have been
identified (Carlson et al., 2008; Elabd et al., 2014; Loffredo(E) Heatmap showing mean mRNA levels for different components of the SASP
(F) ELISA for Il-6 and GM-CSF present in serum of the indicated mice. Data repre
was performed.
(D and E) Three mice were used as young controls while 5 mice were used for o
See also Figure S5.et al., 2013; Sousa-Victor et al., 2019), there are still many unan-
swered questions.
Interestingly, we previously found that sEVs isolated from se-
nescent cells induce paracrine senescence in proliferating cells,
which we termed evSASP (Borghesan et al., 2019; Fafian-Labora
andO’Loghlen, 2020). In this study, we are describing that sEV-Ys
ameliorate senescence in old recipient cells and old mice. Thus,
there seems to be a crosstalk between both cells types via EVs;
EVs inducing senescence in young cells and EVs preventing
senescence in old cells. We believe this situation is what really
happens in vivo. It is known that the tissue holds a mixture of se-
nescent and proliferating cells. We believe that the predominance
of functionality between sEV-Ys and sEV-Os will depend on the
proportion of each cell present in the tissue. When the majority
of cells existing in the tissue are senescent cells, the tissue ho-
meostasis becomes compromised as there is transmission of
paracrine senescence (Borghesan et al., 2019; Acosta et al.,
2013); however, during the earlier stages of aging or during tissue
damage, when there are still plenty of proliferating cells, these can
‘‘repair’’ tissue dysfunction by ameliorating the senescent pheno-
type of damaged cells through soluble factors (Mosteiro et al.,
2016; Ocampo et al., 2016) and via sEVs as shown in this study.
In fact, the temporary presence of senescent cells is generally
beneficial for an individual while the accumulation is detrimental.
Although there is also a huge contribution from the immune sys-
tem in the clearance of senescent cells to improve tissue function,
EVs also play a key role in maintaining tissue homeostasis (Kalluri
and LeBleu, 2020; Lee and Schmitt, 2019; van Niel et al., 2018). It
is therefore feasible that there is a simultaneous contribution of a
variety of mechanisms to keep the tissue homeostasis.
We recently showed that both SF and sEVs can mediate para-
crine senescence, yet lEVs had no functionality (Borghesan
et al., 2019). However, when looking at ameliorating features of
senescence and aging, especially in relation to oxidative stress,
we find that only the sEV fraction is functional. One possible
explanation could be that the SF is immediately oxidized due
to the high levels of ROS present in cells from old donors and
in old mice, while sEV contents are protected due to their mem-
brane layer. This would allow sEVs to be functional both locally
and systemically, as we have seen in the liver, kidney, BAT,
and serum, with sEV-Ys delivered by i.p. injections, but also
the serum during local sEV-Y injections. This is important and
highlights the potential of sEVs as anti-aging therapeutic agents.
In fact, there are several clinical trials evaluating the potential of
sEVs as therapeutic agents in a variety of contexts (Fuster-Mat-
anzo et al., 2015).
GSTM2 is a cytosolic enzyme that catalyzes the conjugation of
GSH aimed at the elimination of ROS-generated toxic byprod-
ucts (Townsend and Tew, 2003). Here, we show that the levels
of GSTM2 decrease during senescence and in aged mice in
accordance with a decrease in its presence in their respective
sEVs. Interestingly, we show that GSTM2 is contained within
sEVs, conferring upon them GST antioxidant activity, whichin liver and kidney from young, old, and old mice treated with sEV-Ys.
sent mean ± SEM of 2 young mice and 5 old mice per condition. Welch’s t test
ld and 5 for old sEV-Y-treated.




Figure 6. sEV-Ys Prevent ROS Accumulation and Increase the Levels of GSH in Old Mice
(A) The levels of oxidative stress (ROS) were measured in liver and serum from youngmice (n = 3 mice) and old mice treated or not with sEV-Ys (n = 5 old mice per
condition). Data represent mean ± SEM. t test analysis was performed.
(B) Representative immunoblot for the expression of GSTM2 in the liver in young and old treated or untreated mice. GAPDH was used as loading control and
quantification of 5 mice per condition is shown in graph.
(C) Measurement of GST activity in the liver and serum from different young, old sEV-Y-treated, or non-treated mice (n = 3 young and n = 5 per condition in old
mice). Data represent mean ± SEM. t test was performed.
(D) qPCR analysis for different transcripts related to the antioxidant pathway in the liver from young, old sEV-Y-treated, or untreated old mice (n = 3 young and n =
5 per condition in old mice). Mann-Whitney test was performed.
See also Figure S6.
ll
OPEN ACCESS Articleameliorates senescence, in contrast to the SF fraction. As
GSTM2-contained sEVs are a limiting factor, we observe they
are the initial trigger of the antioxidant pathway, which needs
to be maintained transcriptionally to see the antioxidant long-82 Cell Metabolism 32, 71–86, July 7, 2020term response we observe in vivo. GST needs the supply of
reduced GSH, which we have shown to be extremely low in
old cells and mice tissue. Thus, we observe increased transcrip-







Figure 7. sEV-Ys Ameliorate Lipid Peroxidation In Vitro and In Vivo
(A and B)MDA levels in (A) liver and (B) serum from young and oldmice treated with sEV-Ys or not. Data represent themean ± SEM of 3–5mice. t test analysis was
performed.
(C) MDA quantification in iRAS cells treated with sEVs from iC or iRAS expressing myc-Gstm2 or not. Data show the mean ± SEM of 3 independent experiments.
*p < 0.05; ns, non-significant.
(D) Quantification of MDA in old donor fibroblasts incubated with sEVs isolated from either young or old donors treated with 20 mM BSO. Graphs represents the
mean ± SEM of 4 old donor fibroblasts. ***p < 0.001; ns, non-significant.
(E) Growth curve for young HFFF2 fibroblasts treated with increasing concentrations of 4-HNE (1.25, 2.5, and 5 mM). iRAS were used as a positive control. Data
represent the mean ± SEM of 3 independent experiments. Two-way ANOVA was performed. ***p < 0.001.
(legend continued on next page)
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the intracellular GSH pool. Furthermore, our data are consistent
with other studies that show that EVs can have independent
metabolic activity. EVs have been shown to have asparaginase
and succinase activity to suppress neuroinflammation (Iraci
et al., 2017; Peruzzotti-Jametti et al., 2018), while nicotinamide
phosphoribosyltransferase (eNAMPT) was shown to be present
within EVs to ameliorate aging. In fact, eNAMPT-EVs can induce
NAD+ in recipient cells and counteract aging (Yoshida et al.,
2019). In spite of all the evidence, we cannot exclude the possi-
bility that additional components within sEV-Ys are also contrib-
uting to prevent the senescent and aging phenotype observed.
One of the main substrates of GSTM2 are lipids. The oxidation
of lipids induces degradation products through a process known
as lipid peroxidation. This results in the generation of highly reac-
tive products such as reactive aldehydes 4-hydroxynonenal (4-
HNE) and malondialdehyde (MDA), which can modify protein
function (Binder et al., 2016). It is interesting that sEV-Ys reduce
4-HNE andMDA levels in the liver, kidney, BAT, and serum in old
mice, although accumulation of 4-HNE has been previously re-
ported in senescence, aging, and age-related diseases (Ade-
mowo et al., 2017; Jurk et al., 2014). In fact, treatment of young
cells with 4-HNE induces senescence, which is prevented by
treatment with sEV-Ys. The importance of senescencemediated
by 4-HNE is highlighted by the use of siRNA and small molecule
inhibitors targeting several pathways important in senescence.
Although it is tempting to speculate that according to our re-
sults sEV-Ys have rejuvenating potential to young tissues in old
mice, we must be cautious to reach such conclusions as more
experimental data would be needed. However, we cannot
deny that sEV-Ys are helping damaged tissues to repair, which
is also a very attractive tool. It would be interesting to perform
longer-term experiments to determine the time period by which
sEV-Ys can have rejuvenating or repairing functions.
Limitations of Study
One caveat of the current study is the use of PBS as a control in
old mice in comparison with sEV-Ys injected into old mice. We
are aware that the ideal control would have been the use of
sEV-Os in old mice as per the in vitro data. We hypothesized,
based on our previous findings (Borghesan et al., 2019), that
sEV-Os might induce paracrine senescence in the few prolifer-
ating cells that old mice have.
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Coppé, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senes-
cence-associated secretory phenotype: the dark side of tumor suppression.
Annu. Rev. Pathol. 5, 99–118.
Dolado, I., Swat, A., Ajenjo, N., De Vita, G., Cuadrado, A., and Nebreda, A.R.
(2007). p38alpha MAP kinase as a sensor of reactive oxygen species in tumor-
igenesis. Cancer Cell 11, 191–205.
Elabd, C., Cousin, W., Upadhyayula, P., Chen, R.Y., Chooljian, M.S., Li, J.,
Kung, S., Jiang, K.P., and Conboy, I.M. (2014). Oxytocin is an age-specific
circulating hormone that is necessary for muscle maintenance and regenera-
tion. Nat. Commun. 5, 4082.
Fafian-Labora, J., and O’Loghlen, A. (2020). Classical and non-classical inter-
cellular communication in senescence and ageing. Trends Cell Biol. Published
online June 3, 2020. https://doi.org/10.1016/j.tcb.2020.05.003.
Fuster-Matanzo, A., Gessler, F., Leonardi, T., Iraci, N., and Pluchino, S. (2015).
Acellular approaches for regenerative medicine: on the verge of clinical trials
with extracellular membrane vesicles? Stem Cell Res. Ther. 6, 227.
Gorrini, C., Harris, I.S., andMak, T.W. (2013). Modulation of oxidative stress as
an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947.
Iraci, N., Gaude, E., Leonardi, T., Costa, A.S.H., Cossetti, C., Peruzzotti-
Jametti, L., Bernstock, J.D., Saini, H.K., Gelati, M., Vescovi, A.L., et al.(2017). Extracellular vesicles are independent metabolic units with asparagi-
nase activity. Nat. Chem. Biol. 13, 951–955.
Jeon, O.H., Wilson, D.R., Clement, C.C., Rathod, S., Cherry, C., Powell, B.,
Lee, Z., Khalil, A.M., Green, J.J., Campisi, J., et al. (2019). Senescence cell-
associated extracellular vesicles serve as osteoarthritis disease and therapeu-
tic markers. JCI Insight 4, e125019.
Jurk, D., Wilson, C., Passos, J.F., Oakley, F., Correia-Melo, C., Greaves, L.,
Saretzki, G., Fox, C., Lawless, C., Anderson, R., et al. (2014). Chronic inflam-
mation induces telomere dysfunction and accelerates ageing in mice. Nat.
Commun. 2, 4172.
Kalluri, R., and LeBleu, V.S. (2020). The biology, function, and biomedical ap-
plications of exosomes. Science 367, eaau6977.
Kuilman, T., Michaloglou, C., Vredeveld, L.C.W., Douma, S., van Doorn, R.,
Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-
induced senescence relayed by an interleukin-dependent inflammatory
network. Cell 133, 1019–1031.
Kuilman, T., Michaloglou, C., Mooi, W.J., and Peeper, D.S. (2010). The
essence of senescence. Genes Dev. 24, 2463–2479.
Lee, S., and Schmitt, C.A. (2019). The dynamic nature of senescence in can-
cer. Nat. Cell Biol. 21, 94–101.
Liao, C.Y., Rikke, B.A., Johnson, T.E., Gelfond, J.A., Diaz, V., and Nelson, J.F.
(2011). Fat maintenance is a predictor of the murine lifespan response to die-
tary restriction. Aging Cell 10, 629–639.
Liu, G.H., Barkho, B.Z., Ruiz, S., Diep, D., Qu, J., Yang, S.L., Panopoulos, A.D.,
Suzuki, K., Kurian, L., Walsh, C., et al. (2011). Recapitulation of premature
ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472,
221–225.
Loffredo, F.S., Steinhauser, M.L., Jay, S.M., Gannon, J., Pancoast, J.R.,
Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J.L., et al.
(2013). Growth differentiation factor 11 is a circulating factor that reverses
age-related cardiac hypertrophy. Cell 153, 828–839.
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2’, 7’ -dichlorodihydrofluorescein diacetate Invitrogen D399
Critical Commercial Assays
Immunofluorescence SA-b-Gal Sigma-Aldrich F2756
SA-b-Gal for tissue sections Canvax CA090
Glutathione S-Transferase (GST) Assay Sigma-Aldrich CS0410-1KT
Lipid peroxidation assay Colorimetric and
Fluorescence
Abcam ab118970
GSH/GSSG-Glo Assay Promega Corporation V6611
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See Table S2 for primers This paper Table S2
siRNA: C/EBPb Horizon Discovery/Dharmacon L-006423-00-0005
siRNA: p16 QIAGEN SI02623747
siRNA: p53 QIAGEN SI02664403
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ER:RASG12V Rapisarda et al., 2017 Rapisarda et al., 2017
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STRING: functional protein association
networks
STRING https://string-db.org
GraphPad Prism 8 GraphPad Software https://www.graphpad.com/scientific-
software/prism/
Other
NTA Calibration Beads (100 nm) Polyscience 24041
10k protein concentration columns EMD Millipore 10088753
qEV columns IZON SP5
ELISA IL-6 Mab Tag GmbH mIL-6-EIA-1
ELISA GM-CSF Mab Tag GmbH mGMCSF-EIA-1
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ana
O’Loghlen (a.ologhlen@qmul.ac.uk).
Materials Availability
No new unique reagents were generated from this study.
Data and Code Availability
The main data from this study has been deposited in Mendeley with the identification number https://doi.org/10.17632/
3kjy2vd2md.1.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Primary Cell Cultures
HFFF2 (Human Caucasian fetal foreskin fibroblasts) were obtained by the Culture Collections (Public Health England, UK; ECACC
86031405). Young, old and progeria-derived primary human fibroblasts were obtained from the Coriell Cell Repository with the
following codes: Young: GM05399 (1 year old; Y1; male), GM00969 (2 years old; Y2; female), GM05565 (3 years old; Y3; male),
GM05758 (1 year old; Y4; male); Old: AG16086 (67 years old; O1; female), AG06240 (80 years old; O2; male), AG13152 (80 years
old; O3; male), AG13222 (81 years old; O4; male); Progeria: AG11572 (2 years old; HGPS1; female), AG06917 (3 years old;
HGPS2; male), AG07493 (2 years old; HGPS3; female), AG10677 (4 years old; HGPS4; male). Cells were maintained in high-glucose,
pyruvate, Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 1% antibiotic-antimycotic solution in a 37C incu-
bator with 5% CO2.
Mice
C57BL/6 WT mice were purchased from Charles River. Sex-matched male mice between 10-12 weeks of age were used as young
mice and between 22-25 months were used for old mice. Mice were housed at 20-24C, 45%–64% humidity, and at a 12-h light/darke2 Cell Metabolism 32, 71–86.e1–e5, July 7, 2020
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OPEN ACCESSArticlecycle. Experimental mice were fed Harlan Teklad pellets 2018 (18% protein). Mice were specific-pathogen free [Health screening
(Full-FELASA profile) was performed annually] and maintained at the animal facility at the Hospital Ramón y Cajal of Madrid (Spain).
All experiments were performed in accordance with legislation in Spain (RD 53/2013) and the European Directive (2010/63/EU) and
approved by the Ethics Committee of the Ramón y Cajal Hospital, Madrid (ES-280790002001).
METHOD DETAILS
Cell Culture, Retroviral and Lentiviral Infections
All cells were washed twice with PBS prior to starting the experiments to remove excess FBSmedia and maintained in sEV-depleted
FBSmedia for the duration of the experiment. FBSwas depleted of sEV by overnight (ON) ultracentrifugation at 100,000 g at 4C (Sor-
vall 100SE Ultracentrifuge). The supernatant was removed and stored in 50mL falcons at 20C until required. CM was collected after
72 h incubation with cells, unless specified otherwise.
Methods used for retrovirus and lentivirus production and infection have been previously described (Acosta et al., 2008; Rapisarda
et al., 2017).
Differential Ultracentrifugation of Several Fractions from Conditioned Medium and sEV Isolation
To isolate the different EV fractions, the protocol of differential ultracentrifugation (Théry et al., 2006, 2018) wasmodified and adapted
(Borghesan et al., 2019). All cells were plated for each individual experiment and thus the conditioned media was only used once.
Briefly, 1x106 early passage donor cells were plated in a 10cm dish (10ml media) for each individual experiment. After 72 h we either
dissected the conditioned media or isolated sEV. For the disection of the CM, whole CM (10ml for one 10cm dish) was collected by
pipetting from the 10cm dish in 50 mL falcon tubes, centrifuged at low speed (2,000 g for 20min; k-factor of the rotor is 41056) to
eliminate dead cells and cellular debris prior to use and split in two. One half was used as whole CM, concentrated and used to treat
12 wells of a 96-well plate while the other half was further processed. From the second half, large EV (lEV) were collected after the
10,000 g centrifugation step for 1 h, washed in 15 mL PBS and spun down again at 10,000 g (k-factor of the rotor is 669) for 1 h. The
soluble fraction (SF) was then filtered through a 0.22mm filter prior to the 100,000 g centrifugation step. The SF was collected after a
1 h and 20min 100,000 g centrifugation step and concentrated using a 10K column (Amicon Ultra-0.5 Filter) at 14,000 g for 10min
obtaining a concentration factor 10X. The final 100,000 g pellet (sEV) was washed once in 15ml of PBS and resuspended in 10%
EV-depleted FBSmedia for the functional cell culture experiments. Each SF, lEV and sEV individual fraction was used to treat 4 wells
of a 96-well plate. In the case of sEV isolation, we resuspend the final 100,000 g pellet in 840 ml EV-depleted media and treated 12
wells of a 96-well plate (plated with 1,500 recipient cells each) with 70ml of the sEV resuspension. Thus, with 10ml of conditioned me-
dia from one 10cm dish (1x106 cells) we treated 12 wells of a 96 well plate. Media with EV-depleted serum (FBS10%) was used as
negative control in most experiments. A Sorvall 100SE Ultra Centrifuge, with a Beckmann Fixed Angle T865 rotor was used for sEV
isolations. The k-factor of the rotor is 2,08.
We have submitted all relevant data of our experiments to the EV-TRACK knowledgebase (EV-TRACK ID: EV200036) (Van Deun
et al., 2017).
Density Gradient sEV Isolation
sEV isolated by serial ultracentrifugation were re-suspended in 1.5 mL of suspension buffer (0.25M sucrose, 10mM Tris pH 8.0 and
1mM EDTA (pH 7.4). They were mixed 1:1 with 60% stock solution of iodixanol/Optiprep. Then, 1.4ml 40% iodixanol, 1.3ml 20%
iodixanol and 1.2ml 10% iodixanol were successively layered on top of the sEV suspension and tubes were centrifuged at
100,000 g overnight, stopping without the break on. After centrifugation, ten fractions of 700ml were collected from the top of the
tube. Fractions were pelleted at 100,000 g for 1 h 20 min and washed with 15 mL PBS at 100,000 g for 1 h 20 min. Finally, they
were re-suspended in 50 ml lysis buffer for immunoblotting analysis.
qPCR Analysis
RNA was isolated using TRIzol Reagent from the cells previously washed with PBS. Tissues were stored in TRIzol and frozen until
further use. cDNAwas generated using the High-Capacity cDNAReverse Transcription Kit according themanufacturers instructions.
qPCRwas performed using SYBRGreen PCRMasterMix on a 7500 Fast SystemRealTime PCR cycler. For Taqman probes, Taqman
Universal Mix was used to detect the presence of human CD63 (Hs01041238_g1) in kidney and liver. GAPDH mouse and human
(Mm99999915_g1 and Hs0276624_g1 respectively) were used as housekeeping genes. Primer sequences are listed in Table S2.
The relative expression was calculated using the DDCt methods using the Ct values generated using the 7500 software version
2.0.6. The data were normalized to a housekeeping gene, RPS14, except for the Taqman probes.
Nanoparticle Tracking Analysis (NTA)
The NanoSight LM10 (Malvern Instruments) was calibrated using Silica Microspheres beads. EVs were diluted in PBS in order to
obtain a particle number between 108 –109 particles. Three measurements of 60 s were taken per each sample and the mean value
was used to determine particle number. The movement of each particle in the field of view was measured to generate the average
displacement of each particle per unit time, which was calculated using the NTA 3.0 software.Cell Metabolism 32, 71–86.e1–e5, July 7, 2020 e3
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Cells were incubated with 33 mMof the b-galactosidase substrate C12FDG (Fluorescein di-B-D-galactopyranose) in medium supple-
mentedwith 0.5% (v/v) FBS-depleted sEV for 8 h at 37 C. After the incubation, the cells were washedwith PBS and fixedwith 4% (v/v)
paraformaldehyde for 15 min at room temperature.
b-Galactosidase Staining for Mouse Tissue Sections
Liver, kidney and lungwere fixed using paraformaldehyde 4% (v/v) for 1 h. Tissue sections were stained with Galactosidase Assay Kit
overnight at 37C. Then, the tissues were embedded in paraffin. Tissue sections from frozen BAT in OCT were incubated with Galac-
tosidase Assay Kit overnight at 37 C.
Immunofluorescence Staining in Cells
The cells were washedwith PBS and fixed in 4% (v/v) paraformaldehyde for 15min at room temperature. After, the cells were washed
in PBS twice and permeabilized with 0.2% (v/v) Triton X-100. Then, the cells were blocked with 1% (m/v) BSA and 0.2% (m/v) gelatin
fish. Cells were incubated with the suitable concentration of primary antibody (Table S3) and for BrdU detection, the cells were incu-
bated with 0,5 U/ml DNaseI and 3 mMMgCl2 overnight at 4C. The next day, the preparations were washed twice with PBS and incu-
bated with DAPI and secondary antibody. Finally, the cells were washed with PBS twice and the IF preparation are maintained with
PBS and stored at 4C until the acquisition of pictures using INCell 2200 automatized microscope.
High Content Analysis (HCA) Immunofluorescence in Cells
The images of immunofluorescence were acquired using the automated high throughput fluorescent microscope IN Cell Analyzer 2000
witha Å~20objective.Thefluorophores inwavelengthsettingswereused togenerate the IF images (‘DAPI’ forDAPI, ‘FITC’ forAlexaFluor
488 FITC, and ‘Cy50 for AlexaFluor647). Multiple fields per well were acquired to include a minimum of 100 cells per sample well.
High content analysis (HCA) of the images were processed using the INCell Investigator v.2.7.3 software as described previously
(Borghesan et al., 2019; Rapisarda et al., 2017). DAPI was used as a nuclear mask and a top-hat method allowed the segmentation of
cells. To detect cytoplasmic staining in cultured cells, a collar of 7–9 nm around DAPI was applied. Nuclear staining in the reference
wavelength, that is all the other wavelengths apart from DAPI, was quantified as an average of pixel intensity (gray scale) within the
specified nuclear area. Cytoplasmic IF staining was quantified as a coefficient of variance of the pixel intensities within the collar area
in the reference wavelength. In samples of cultured cells, a threshold for positive cells was assigned above the average intensity of
unstained or negative control samples.
Immunofluorescence Staining in Tissues
Tissue sections were washed three times with PBS were permeabilized with 0.1% Triton X-100 for 15 min, then washed three times
with PBS and blocked in 2% blocking buffer solution for 1 h at room temperature. Next, sections were incubated overnight with pri-
mary antibody at optimizated concentration (Table S3) in blocking buffer solution at 4C, washed three times in PBS and incubated
for 2 h with secondary antibodies diluted 1:200 in blocking buffer solution. Afterward, they were washed three times in PBS and the
coverslips mounted on slides with DAPI-containing mounting solution. The acquisition of pictures was performed using a Nikon
ECLIPSE Ti-e inverted microscope.
GST Activity
The tissues, serum, cells or sEV were homogenized in ice-cold Tris-HCl buffer (40 mM, pH 7.4). Then, the homogenized tissues were
diluted 1:2 in RIPA Buffer. GST activity was determined using CDNB (S-2,4-dinitrophenyl glutathione). The homogenized tissues,
cells or sEV were mixed with 20 mM L-Glutathione reduced and 10 mM CDNB in Dulbecco’s phosphate Buffered Saline (DPBS).
The formation of the adduct of CDNB was monitored by measuring the rate of increase in absorbance at 405 nm for 5 min using
a TECAN XFLUOR microplate reader.
Detection of ROS
ROS in tissues was estimated as following; tissues were homogenized in ice-cold Tris-HCl buffer (40 mM, pH 7.4) (different propor-
tions depend on the tissue). Samples of tissue homogenate were mixed with 2’, 7’ -dichlorofluorescein diacetate (1 mM) prepared in
Tris-HCl buffer (40 mM, pH 7.4). The mixture was incubated for 30 min at 37C. Finally, the fluorescence intensity of the samples was
measured using a TECAN XFLUOR microplate reader (lexcitation 485 nm and lemission 525 nm).
To determine the levels of ROS in cells by FACS, the cells were incubated with DCFH 1 mM for 30 min at 37C. Then, they were
washed with PBS three times. The data was acquired using NovoCyte Flow Cytometer with a 488nm laser. Gates were set using
the NovoExpress Software to analyze single cells fluorescence.
Measure of Malondialdehyde (MDA)
Tissueswere homogenizedwith Tris-HCl buffer (40mM, pH 7.4). Then, the homogenized tissueswere dilutedwith RIPABuffer 1:2. To
evaluate the levels of MDA we used the Thiobarbituric Acid Reactive Substances (TBARS) Assay. The samples were incubated with
5.3 mg/ ml thiobarbituric acid diluted in acid acetic and NaOH buffer for 1 h at 100C. Finally, the absorbance was measured using a
TECAN XFLUOR microplate reader at 540 nm.e4 Cell Metabolism 32, 71–86.e1–e5, July 7, 2020
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instructions. The absorbance was measured at 532 nm using Synergy HT-Multi-Mode Microplate Reader.
Determination of GSH and GSSG
Total glutathionewas extracted from the tissues using 0.4 N perchloric acid (PCA) for 30min at 4C, and centrifuged at 12,000 rpm. Total
glutathione levels weremeasured in 96-well plates by the addition of 5,50 dithio-bis-2-nitrobenzoic acid (0.6 mM), NADPH (0.2mM) and
glutathione reductase (1U) and the reaction was monitored at 405 nm for 6 min using a TECAN XFLUOR microplate reader. Oxidized
glutathione (GSSG) was measured as following; briefly, after PCA extraction, reduced glutathione (GSH) was derivatized with 2-vinyl-
pyridine at room temperature for 1 h, and the reaction was monitored as above. Reduced GSH was obtained by subtracting GSSG
levels from total glutathione levels. To determine the ratio GSH/GSSG in cells and serum a luminescent-based assay kit was used.
Isolation of Serum from Mouse Blood
2 mL of blood from mice was centrifuged at 2,000 xg for 10 min at 4C. After, the serum was isolated, aliquoted and stored at 80 C
until needed.
ELISA
Mouse serum samples were analyzed to quantify the amount of IL6 and GM-CSF (Mab Tag GmbH) using an immune-assay ELISA.
The absorbance was measure at 540 nm using Synergy HT-Multi-Mode Microplate Reader.
siRNA Reverse Transfection
HFFF2 fibroblast were reverse transfected with 50 nM siRNAs on a 96-well plate. After 24 h, the medium was changed. Two days
later, the cells were washed and incubated with 2.5 mM 4-HNE in medium supplemented with 10% (v/v) FBS-depleted sEV and
1% (v/v) A/A for 6 days.
Treatments with 4-HNE
Young HFFF2 fibroblasts were treated with increasing concentrations of 4-HNE (1.25, 2.5 and 5 mM) in medium supplemented with
10% (v/v) FBS-depleted sEV and 1% (v/v) A/A for 6 days. Then, the cells were washed and treatedwith 100nMNAC, 100nMVitamin C
or 20 mM CAY10576.
Immunoblot
sEV and cells were lysed using the following lysis buffer [(Tris-HCl 20 mM pH 7.6; DTT 1mM; EDTA 1mM; PMSF 1mM; benzamidine
1 mM; sodium molybdate 2 mM; b- sodium glycerophosphate 2 mM; sodium orthovanadate 0.2 mM; KCl 120 mM; 1 mg/mL (each)
leupeptin, pepstatin A and antipain; NonidetTM P-40 0.5% (v/v); Triton X-100 0,1% (v/v)].
The protein from cell lysates were quantified using the Advance Protein Assay Reagent and for homogenized tissues by BCA assay
kit (Thermo Fisher Scientific). Lysates were diluted with 4X Laemmli Sample Buffer and equal quantities of total protein were sepa-
rated in SDS-PAGE gels, transferred to a PVDF 0.45mmpore sizemembrane and probedwith different antibodies (Table S2). Protein
bands were detected using a SuperSignal West Pico PLUS Chemiluminescent Substrate and the ChemiDoc XRS+ System.
Transfection of Recombinant GSTM2 into sEV
sEV from old or young fibroblasts were isolated by ultracentrifugation and incubated with 1 mg/mL His-Tagged recombinant GSTM2
protein (rGSTM2) and 0.1 mg/ml Lipofectamine2000. sEVs were then purified using commercial SEC columns to remove excess
rGSTM2, pooled together, ultracentrifuged again at 100,000 g for 1 h 20min again andwashedwith 15mL PBS. 10 ng/mL of rGSTM2
on its own was used as a positive control.
Mice Experiments
Male C57BL/6 mice aged 3 months for young and 22-25 month-old mice were used for this study. Intraperitoneal injections (IP) were
performed every 3 days to inject either 20 mg of isolated sEV or an equivalent volume of PBS for 3 weeks. Subcutaneous injection were
performed injecting 20 mg of sEV or PBS for 2 weeks. Mice were sacrificed 24 h after the last injection. Tissues were divided in sections
and stored adequately according to the analysis to be performed. All procedures used in animal experiments followed Spanish (RD 53/
2013) and European legislation (2010/63/EU) and were previously approved by the Ramón y Cajal Hospital Ethics Committee (Spain).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Statistical analysis was performed using Student’s t test except if specified otherwise in the figure legend. Results are expressed as
the mean ± SD or SEM except were indicated otherwise. A p value was considered significant as the following: * p < 0.05; ** p < 0.01;
*** p < 0.001. Data were plotted and analyzed using GraphPad Prism 8 or Microsoft Excel 16 software.Cell Metabolism 32, 71–86.e1–e5, July 7, 2020 e5
